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A B S T R A C T   
The development of therapeutics in oncology is a highly active research area for the pharmaceutical and 
biotechnology industries, but also has a strong academic base. Many new agents have been developed in recent 
years, most with specific biological targets. This has mandated the need to look at different ways to streamline 
the evaluation of new agents. One solution has been the development of adaptive trial designs that allow the 
evaluation of multiple agents, concentrating on the most promising agents while screening out those which are 
unlikely to benefit patients. Another way forward has been the growth of partnerships between academia and 
industry with the shared goal of designing and conducting high quality clinical trials which answer important 
clinical questions as efficiently as possible. 
The RAMPART trial (NCT03288532) brings together both of these processes in an attempt to improve out-
comes for patients with locally advanced renal cell carcinoma (RCC), where no globally acceptable adjuvant 
strategy after nephrectomy currently exist. RAMPART is led by the MRC CTU at University College London 
(UCL), in collaboration with other international academic groups and industry. We aim to facilitate the use of 
data from RAMPART, (dependent on outcomes), for a future regulatory submission that will extend the license of 
the agents being investigated. We share our experience in order to lay the foundations for an effective trial design 
and conduct framework and to guide others who may be considering similar collaborations. 
Trial Registration: 
ISRCTN #: ISRCTN53348826, 
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NCT #: NCT03288532, 
EUDRACT #: 2017–002329-39. 
CTA #: 20363/0380/001–0001. 
MREC #: 17/LO/1875. 
ClinicalTrials.gov Identifier: NCT03288532 
RAMPART grant number: MC_UU_12023/25. 
. 
RAMPART Protocol version 5.0.   
1. Background 
Largescale phase III randomised controlled trials have evaluated 
various oral tyrosine kinase inhibitors (TKIs) after nephrectomy, for 
localised RCC. None have shown overall survival (OS) benefit in this 
setting [1–4]. Therefore, nephrectomy followed by active surveillance 
for relapse, remains the most common global standard of care. Patients 
with intermediate or high-risk RCC after surgical resection, as assessed 
by renal cancer specific prognostic scores, remain at significant risk of 
relapse and death [5]. An effective adjuvant strategy for all patients with 
locally advanced RCC remains an unmet clinical need. 
Clinical trials of adjuvant therapies in RCC are a notoriously chal-
lenging and lengthy undertaking. They require a large network of 
collaborating groups and investigators to meet accrual targets and an 
inherently lengthy follow-up period owing to relatively distant outcome 
measures. At the MRC CTU at UCL, we have a rich experience of leading 
successful large, international collaborative trials in various disease 
types, including SORCE (NCT00492258) our previous trial in the adju-
vant RCC setting [1]. We also have expertise in the development and 
evaluation of novel trial designs to streamline the evaluation of new 
therapies [6]. We have leveraged both of these capabilities to develop 
the RAMPART trial (NCT03288532); an international phase III rando-
mised multi-arm, multi-stage (MAMS) platform trial of adjuvant im-
mune checkpoint inhibitors (ICIs) in treatment of locally advanced RCC. 
In this paper, we describe the clinical rationale behind the agents 
used in RAMPART. We outline the MAMS design and explain the choice 
of control arm, study population and primary outcome measures. We 
detail features influenced by collaboration with leading international 
academic groups, with industry partners (AstraZeneca AZ), and the 
scientific advice we received from the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) during the design 
phase. We do this to demonstrate the necessary steps for developing an 
efficient international academic led trial, ready to meet standards 
compatible with future regulatory submission. In doing so, we aim to 
accelerate the development of effective adjuvant treatments for patients 
with locally advanced RCC. 
2. Rationale for a trial of adjuvant ICIs for locally advanced RCC 
Types of ICI therapy include antibodies against cytotoxic T- 
lymphocyte associated antigen 4 (anti-CTLA-4) and programmed cell 
death protein 1 / programmed cell death protein ligand 1 (anti-PD-1/ 
PDL-1). In recent years, ICIs have revolutionized the treatment options 
available in both the adjuvant and advanced setting for patients with 
various cancers, including lung and melanoma [7–9]. In advanced RCC, 
promising results have been observed with combination ICI therapies - 
for example ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) 
[9,10] as well as the combination of ICI therapies with tyrosine kinase 
inhibitors (TKIs) [11–13]. In this context, an investigation of ICIs in the 
setting of locally advanced RCC is justified. 
In RAMPART, we are investigating the PDL-1 inhibitor durvalumab 
as monotherapy (Arm B) and in combination with the CTLA-4 inhibitor 
tremelimumab (Arm C) after complete surgical excision of RCC. 
3. Trial oversight and academic collaboration 
At the very outset of planning a trial that might succeed SORCE, we 
developed a RAMPART Trial Management Group (TMG). The TMG 
brings together an international network of experts in the field of RCC, a 
number of patient representatives, and the trial team at the MRC CTU at 
UCL. This key collaboration has played the central role in shaping the 
design of RAMPART and has retained overall oversight as the trial has 
progressed. 
UCL, as the host organisation for the MRC CTU at UCL, is the Sponsor 
of RAMPART. In order to extend RAMPART’s reach internationally, UCL 
entered into collaborative agreements with the Australian and New 
Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Uni-
versity of Sydney, UNICANCER and Vall d’Hebron Institute of Oncology 
(VHIO). In order to develop a foundation for consistent trial conduct 
across countries, these agreements lay out the specific roles and re-
sponsibilities of the MRC CTU at UCL and those of each of our interna-
tional collaborators. 
RAMPART is currently the only international academic led multi- 
arm trial investigating ICIs in the adjuvant RCC setting; this is possible 
because of our unique multi-disciplinary international collaborations. 
4. Collaboration and engagement with industry partners and 
regulators 
UCL and AZ entered into early discussions outlining our respective 
requirements for a collaboration. As academic partners, we at UCL 
wanted overall Sponsorship of the trial and responsibility for the trial 
data. For the statistical analysis we requested that overall survival (OS) 
should be a co-primary outcome measure with disease free survival 
(DFS). There were also a number of trial conduct requests from UCL. We 
were keen to explore an ICI as monotherapy and separately, two ICIs in 
combination, within a single trial. We also wanted to be able to add an 
additional experimental arm, even one from another company, at some 
stage during trial conduct. AZ requested the development of a robustly 
designed trial, one that could be delivered within a suitable timeframe 
and had the potential to facilitate a future regulatory submission. 
The team of senior statisticians and trial methodologists at the MRC 
CTU at UCL and the Chief Investigator entered into critical early dis-
cussions with AZ to ensure that both sets of needs were met. UCL and AZ 
entered into a start-up agreement, which provided critical initial fund-
ing to the MRC CTU at UCL to allocate staff and time to initiating the 
project. The start-up agreement facilitated a full collaboration agree-
ment between UCL and AZ as the trial developed further. 
In parallel, AZ applied for both a pre-Investigational New Drug Type 
B meeting with the FDA and also a request of Scientific Advice / Protocol 
Assistance to the EMA jointly on behalf of AZ and UCL as Sponsor. We 
worked in partnership with AZ on the briefing document that was sub-
mitted for review. Discussions with the agencies centred on the statis-
tical analysis plan for RAMPART’s MAMs design, including the approach 
to the interim analyses, the appropriateness of the co-primary outcomes 
of disease free survival (DFS) and overall survival (OS), the risk pop-
ulations to include and the use of active monitoring as the control arm. 
We were able to discuss and agree the specific details of each of these 
features with our TMG in advance of discussions with the regulators. Our 
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experience of the discussions with regulators is that the FDA have a more 
overarching approach to trials and trialists whereas the EMA appoint 
rapporteurs from the different member states and so comments tend to 
be based on individual rather than organisational perspective. 
Our strong working relationship with colleagues in AZ has been 
critical to the development and efficient conduct of RAMPART. Over 
time we have discussed and agreed a mutually acceptable data collec-
tion plan, we share relevant safety information with each other and we 
meet regularly to provide feedback on operational aspects of the trial. 
AZ review protocol amendments and any publications arising from the 
trial, but otherwise have no input into the day-to-day running of the 
trial. We would recommend this model of clear communication and a 
willingness to collaborate, including joint discussions with regulators, 
with others who are embarking on similar trial partnerships. 
5. RAMPART trial design 
5.1. The case for an adaptive MAMS platform trial in adjuvant RCC 
At MRC CTU at UCL, we have rich experience of designing and 
running MAMS trials. The STAMPEDE trial in prostate cancer is the MRC 
CTU at UCL’s flagship MAMS trial. Since the trials initiation in 2005, the 
STAMPEDE team have reported results on seven randomised compari-
sons (each of which could be considered a trial within a single over-
arching master protocol) [14–20] and will report on at least another 
four, with many more future comparisons under consideration. 
The multi-arm design of RAMPART (Fig. 1) allows the investigation 
of durvalumab (anti-PDL-1) as monotherapy (Arm B) and separately in 
combination with tremelimumab (anti-CTLA-4) (Arm C), within the 
scope of a single trial. Furthermore, the platform allows the addition of 
new research arms, involving promising agents or combinations within 
an already recruiting trial. Importantly the addition of one arm (Arm D) 
is embedded in the original statistical design assumptions [21]. In a 
multi-arm setting, there are two different measures of type I error rate: 
the pairwise type I error rate (PWER) and the family-wise type I error 
rate (FWER) [22]. In RAMPART, the overall type I error rate – i.e. the 
FWER [22], is strongly controlled at 2.5% for all the pairwise compar-
isons whether or not a new research arm is added. The PWER is the 
probability of incorrectly rejecting the null hypothesis for the primary 
outcome in a particular experimental arm, regardless of outcomes in the 
other experimental arms [22]. For each pairwise comparison in the 
RAMPART trial, we calculated the PWER both analytically and using 
simulations considering two scenarios: A) the trial starts (and possibly 
concludes) with two research arms; and B) a new research arm is added 
before accrual to the current 3-arm trial completes. The results from our 
simulations show that the final stage significance level of 0:0097 in all 
pairwise comparisons controls the overall FWER at 2.5% when the 3rd 
research arm is added later on (i.e., scenario B). Further simulation 
studies also showed that the final stage significance level of the two 
original pairwise comparisons can be increased to 0.014 if the deferred 
arm is not added (i.e., scenario A) to buy back the unspent type I error of 
the third pairwise comparison. We applied Dunnett’s approach to 
empirically calculate the FWER in both scenarios A and B. By strongly 
controlling the FWER at 2.5% (one-sided), RAMPART is robustly 
designed for both eventualities. The relevant methods to calculate the 
correlation structure are described in Choodari-Oskooei et al. [22]. 
RAMPART’s multi-stage design includes pre-planned, time-to-event 
driven interim analyses for both lack of benefit and overwhelming 
benefit. Lack of benefit analyses allow the cessation of recruitment to 
treatment arms where treatments offer no effect, which means partici-
pant accrual can be focused on the more promising research arms and 
the control arm. The planned overwhelming benefit analysis allows the 
reporting of results earlier if sufficient benefit is observed. In all com-
parisons, a constant stopping boundary (i.e. Haybittle-Peto type) is used 
at all interim stages for overwhelming efficacy. The overall type I error 
rate was adjusted for any multiplicity as a result of interim analysis. 
Importantly, it was agreed with regulators that interim data showing 
overwhelming benefit could support an early submission of licensing 
extension for durvalumab to include treatment of locally advanced RCC 
after nephrectomy. The timelines for all analyses and stopping guide-
lines as planned at the outset of the trial are described in detail in our 
trial protocol, currently version 5.0 [23]. 
An additional adaptive feature of the MAMS design is that the control 
arm can be altered if the recognised standard of care changes. If we were 
to change the control arm according to new standard of care treatments 
for patients with locally advanced RCC, we would revisit the design 
assumptions and recalculate the sample size to maintain the statistical 
integrity of the trial. We would be able to make this change as a protocol 
amendment rather than starting a new trial. RAMPART’s MAMS design 
therefore gives us the greatest opportunity to fulfil the goal of improving 
outcomes for patients with RCC as rapidly and efficiently as possible. 
5.2. Choice of control arm 
Previous trials in the adjuvant RCC setting tended to use placebo 
controls and blinding of patients to treatment arms when the agents 
were administered orally. In RAMPART, certain toxicities for both the 
ICI agents are expected, which will likely be more obvious in the com-
bination arm. Therefore, to minimise the burden to both patients and 
healthcare systems, we decided not to include an intravenous placebo. 
Consequently, our control arm is ‘active monitoring’ and treatment 
allocation is not blinded. The results from ASSURE, PROTECT, STRAC 
and more recently the SORCE trial have shown no overall survival 
benefit for TKIs over placebo in the adjuvant RCC setting [1–4] giving us 
confidence that active monitoring by clinical and radiological means is 
the most appropriate control for RAMPART. All patients are 
Fig. 1. RAMPART trial - adaptive design.  
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radiologically monitored at the same frequency to standardize follow-up 
of all arms thereby minimising bias in reporting disease relapse. To 
optimize compliance, we underline the importance of adhering to 
follow-up schedules in the information that we provide to patients and 
sites. In addition, where deemed appropriate by the investigator, there is 
a greater emphasis on providing remote clinical assessments since the 
COVID-19 pandemic, which improves upon flexibility for patients on all 
arms. 
5.3. Choice of dosing schedule in the combination arm 
As with all treatments, ICIs have recognised side-effects. The impact 
and risk of side-effects caused by treatments may be very different in an 
adjuvant setting where patients may already be surgically cured, and has 
been rigorously considered by the RAMPART TMG. The dose of the anti- 
CTLA-4 agent, both as a single agent and in combination with anti-PD-1/ 
PD-L1 agents, appears to be the more dominant driver of toxicity. 
Although most trials to date have used four cycles of combination ICI 
therapy, there is no strong scientific rationale for this duration. In 
RAMPART, we have opted for two cycles of the anti-CTLA/anti-PD-L1 
combination followed by single-agent durvalumab for the remainder 
of the year in the combination therapy arm (Arm C). This decision re-
flected our responsibility to select a treatment strategy that balances the 
optimal potential for efficacy with an acceptable safety profile for pa-
tients with locally advanced RCC. In line with comments from the reg-
ulators, we have given patients sufficient information regarding the 
potential benefits and risks of durvalumab and tremelimumab and we 
agreed to hold our Independent Data Monitoring Committee (IDMC) 
meetings every 6 months in the early years of the trial. 
5.4. Choice of study population 
A key challenge in any adjuvant trial relates to how to how best to 
characterise and stratify patients according to their risk of relapse for the 
purposes of trial eligibility. The Leibovich score [24] was a pragmatic 
choice by the RAMPART TMG as all component prognostic factors are 
required as part of routine pathology reporting in RCC, thus negating the 
need for additional expertise or training for its calculation. Furthermore, 
clinical markers such as patient’s performance status or symptoms at 
baseline are not included, reducing the chance of subjective bias in its 
assessment. 
The next challenge was to choose the risk populations eligible for the 
trial. Confining the RAMPART population to Leibovich high risk (score 6 
≤) would limit patient recruitment but minimise the exposure of lower 
risk patients to potential drug toxicity. However, intermediate risk pa-
tients (scores 3–5) also have a substantial risk of relapse and death from 
RCC [24], highlighting the clinical dilemma if we were to exclude these 
patients entirely. Therefore, we included patients at intermediate risk of 
recurrence in RAMPART. We accounted for the treatment effect of the 
intermediate risk patients by entering them early to the trial, knowing 
that events are likely to occur later than in high risk patients and by 
capping their accrual at 25% of the total. Therefore, intermediate risk 
patients will contribute enough events to the primary DFS analysis and, 
should the trial yield a positive outcome, licensing may be extended to 
this cohort of patients. 
5.5. Choosing co-primary outcome measures 
We designed RAMPART to investigate two co-primary outcome 
measures: DFS and OS. DFS is the standard primary outcome in adjuvant 
trials, both in RCC and in a range of other cancers. New agents are often 
licensed based on this outcome. 
OS remains a key survival outcome, particularly for patients and 
healthcare providers. However, in the setting of renal cancer, an adju-
vant trial focussing only on OS would take up to 20 years to report its 
results, potentially denying thousands of patients the opportunity to 
benefit from what may prove to be efficacious treatments. Pragmati-
cally, we will analyse OS conditional on getting a signal in DFS. The 
primary OS analysis will include patients in the high-risk subgroup only 
to avoid the dilution of treatment effect due to high competing causes of 
death in the intermediate risk group. In response to comments from the 
regulators, we also updated the analysis plan to include an interim 
analysis of OS at the time of the interim and final DFS analyses. 
5.6. Regulatory-future proofing –trial conduct 
We have implemented sufficient elements from the outset of the trial 
to enable compliance with International Conference on Harmonisation – 
Good Clinical Practice (both retrospectively and prospectively). This 
will enable data from the RAMPART trial to be used as part of a licensing 
application. We have also put in place a number of notable future- 
proofing trial conduct features, which will facilitate a future regulato-
ry submission. 
Firstly, we have set up our clinical records database to be Clinical 
Data Interchange Standards Consortium (CDISC) compatible. This will 
help facilitate the submission of standardised data to the regulators and 
has the added benefit of facilitating data sharing with other 
organisations. 
Secondly, we have built a CT scan repository to collect CT scans on an 
ongoing basis. In the first instance, sites are sending medical images to 
the MRC CTU at UCL for upload, but eventually trial sites will be able to 
remotely upload and anonymise medical images to the repository. This 
will allow CT scan images to be accessed at crucial time points should 
blinded central review be required. 
Finally, we have implemented a risk-based quality management and 
monitoring plan for RAMPART including both central and on-site 
monitoring. As is appropriate for international trials, the oversight 
plan includes measures to ensure the appropriate and consistent conduct 
of RAMPART at all of our participating sites around the world. Our clear 
quality management plan gives us confidence in the integrity of the data 
as well as in the quality and consistency of trial conduct across all of our 
sites. 
6. Conclusion 
We have carefully designed and planned the RAMPART trial, draw-
ing from the experience our unit offers in the development of MAMs 
trials and our experience leading the SORCE trial in the adjuvant RCC 
setting. We have built an international multidisciplinary, academic team 
to fine-tune an RCC specific adaptive platform. Finally, we sought the 
advice of both European and US regulators in designing our trial. We 
propose this model of working collaboratively from the outset with in-
dustry and regulatory bodies to shape trial design and conduct, in order 
to optimise futureproofing and ensure accountability for decision- 
making. Ultimately, we intend to show that efficient trial design and 
strategic collaborations between academia and industry partners can 
help patients get access to novel treatments sooner. 
Fig. 1 shows the RAMPART trial design, including the timelines for 
analysis proposed at the outset of the trial. The option of adding a third 
research arm is accounted for in the trial design. The timing of when that 
arm might be added has not been decided. A contemporaneous control 
arm would continue for the duration of the trial. 
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Trial status 
The trial is currently open to recruitment. 
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